Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Abicipar Pegol in Neovascular AMD
NCT02859766Phase 1Completed
- Sponsor
- Allergan
- Start
- Dec 2016
- Primary completion
- Oct 2017
- Modality
- Carrier/Scaffold Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abicipar pegol in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Allergan. Primary endpoints: Peak Serum Concentration at Week 20, Serum Concentration Immediately before Next Dose at Week 20 and 4 more. Started Dec 2016; status: completed.
02
Drugs
abicipar pegol
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02859766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859766.